Retatrutide's bioavailability via subcutaneous injection is approximately 95% per Phase 1 pharmacokinetic data (Coskun et al., 2022), meaning very little drug is lost at the injection site regardless of which approved location you choose
Disqualifying conditions include a history of Diabetes, Kidney Disease, Gallbladder Disease, Pancreatitis, Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Syndrome Type 2, Thyroid Nodule that has not been evaluated, Pregnant or Breastfeeding Medical studies report patients losing 15-20% of their body weight on average after one year
The meta-analysis data shows mean reductions of 23.51 mg/dL in fasting plasma glucose and 0.91 percent in HbA1c
Side Effects of Retatrutide: What the Trial Data Shows Retatrutides side effect profile is broadly consistent with other GLP-1 medications, with additional considerations at higher doses